Compare WALD & TNXP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | WALD | TNXP |
|---|---|---|
| Founded | 1988 | 2007 |
| Country | United Kingdom | United States |
| Employees | 364 | 142 |
| Industry | Package Goods/Cosmetics | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 179.6M | 169.8M |
| IPO Year | N/A | 2008 |
| Metric | WALD | TNXP |
|---|---|---|
| Price | $1.86 | $11.35 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 3 | 0 |
| Target Price | ★ $2.00 | N/A |
| AVG Volume (30 Days) | ★ 605.0K | 522.0K |
| Earning Date | 03-13-2026 | 05-11-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 91.75 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $13,107,000.00 |
| Revenue This Year | $9.89 | $558.11 |
| Revenue Next Year | $4.31 | $38.29 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ 29.85 |
| 52 Week Low | $0.72 | $10.03 |
| 52 Week High | $3.22 | $69.65 |
| Indicator | WALD | TNXP |
|---|---|---|
| Relative Strength Index (RSI) | 64.24 | 41.50 |
| Support Level | $1.77 | N/A |
| Resistance Level | $2.03 | $14.85 |
| Average True Range (ATR) | 0.20 | 0.91 |
| MACD | 0.02 | -0.13 |
| Stochastic Oscillator | 85.44 | 32.77 |
Waldencast PLC is a beauty and wellness operating platform. The company is organized into two reportable segments namely Obagi Skincare and Milk Makeup. The company generates the majority of its revenue from the Obagi Medical segment. The Obagi Medical segment is engaged in developing, marketing, and selling skin health products. The Milk Makeup segment includes developing, marketing, and selling cosmetics, skincare, and other beauty products. Geographically the company generates the majority of its revenue from North America region.
Tonix Pharmaceuticals Holding Corp is a fully-integrated biopharmaceutical company commercializing and developing therapies for central nervous system (CNS) disorders, immunology, infectious diseases, and rare diseases. Its portfolio consists of commercial, development and discovery-stage programs, TONMYA, an approved treatment for fibromyalgia, as well as marketed acute migraine products Zembrace SymTouch and Tosymra. The company is conducting clinical trials to evaluate TONMYA for additional indications such as depressive disorder and acute stress disorder. It is also advancing a pipeline of immunology programs, including monoclonal antibody TNX-4800 for Lyme disease prophylaxis and TNX-1500, a third-generation CD40 ligand inhibitor for the prevention of kidney transplant rejection.